- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- PF-05175157, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Orlando, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 793–816
of 3,448
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Metastatic Renal Cell Carcinoma
- Interventions
- placebo, Sorafenib
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Breast Cancer, Breast Neoplasms
- Interventions
- Taxane, Vinorelbine, Ixabepilone, Eribulin, Chemotherapy
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Thrombosis
- Interventions
- xisomab 3G3- Dose 1, xisomab 3G3-Dose 2, xisomab 3G3-Dose 3, xisomab 3G3- Dose 4, Placebo
- Drug · Other
- Lead sponsor
- Aronora, Inc.
- Industry
- Eligibility
- 18 Years to 48 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Healthy Participants
- Interventions
- TAK-994, TAK-994 Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 121 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 2
- States / cities
- Glendale, California • Salt Lake City, Utah
- Conditions
- Schizophrenia
- Interventions
- AZD0328, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 2
- States / cities
- Garden Grove, California • Glendale, California
- Conditions
- Spasticity Due to Cerebral Palsy
- Interventions
- Zanaflex Capsules
- Drug
- Lead sponsor
- Acorda Therapeutics
- Industry
- Eligibility
- 2 Years to 16 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- Cystic Fibrosis
- Interventions
- VX-661, Ivacaftor, Placebo matched to VX-661, Placebo matched to ivacaftor
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 194 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Oakland, California • Boise, Idaho + 16 more
- Conditions
- Healthy
- Interventions
- PF-08049820, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 71 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Thyroid Eye Disease
- Interventions
- Efgartigimod PH20 SC, Placebo PH20 SC
- Combination Product · Other
- Lead sponsor
- argenx
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 16
- States / cities
- Beverly Hills, California • Irvine, California • Los Angeles, California + 13 more
- Conditions
- Dyslipidemia, Hypercholesterolemia, Hypertriglyceridemia
- Interventions
- CAT-2003, Placebo, Statin
- Drug
- Lead sponsor
- Catabasis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 69 Years
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 13
- States / cities
- Muscle Shoals, Alabama • Los Angeles, California • Jacksonville, Florida + 7 more
- Conditions
- Hematologic Malignancies
- Interventions
- APG-2575
- Drug
- Lead sponsor
- Ascentage Pharma Group Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 3
- States / cities
- Jacksonville, Florida • Durham, North Carolina • Houston, Texas
- Conditions
- Healthy Volunteers
- Interventions
- TS-161, TS-161 Placebo
- Drug
- Lead sponsor
- Taisho Pharmaceutical R&D Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Mild Dyslipidemia
- Interventions
- ETC-1002 or placebo
- Drug
- Lead sponsor
- Esperion Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Kalamazoo, Michigan
- Conditions
- Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis
- Interventions
- CYT387
- Drug
- Lead sponsor
- Sierra Oncology LLC - a GSK company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 166 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 3
- States / cities
- Stanford, California • Boston, Massachusetts • Rochester, Minnesota
- Conditions
- Pain, Acute
- Interventions
- Methadone hydrochloride, Morphine Sulfate
- Drug
- Lead sponsor
- simon.haroutounian
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Interventions
- NHT102, DryNeb
- Drug · Device
- Lead sponsor
- Nob Hill Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2030
- U.S. locations
- 1
- States / cities
- Canton, Ohio
- Conditions
- Mycobacterium Avium-Intracellulare Infection, HIV Infections
- Interventions
- Ethambutol hydrochloride, Rifabutin
- Drug
- Lead sponsor
- Pharmacia
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Glioblastoma, Recurrent Glioblastoma
- Interventions
- VB11, Surgery, Placebo, Bevacizumab
- Drug · Procedure · Other
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Boston, Massachusetts • San Antonio, Texas + 1 more
- Conditions
- Prostate Cancer, Breast Cancer, Cutaneous T-Cell Lymphoma, Lung Cancer, Melanoma
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 484 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2024
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- COVID 19
- Interventions
- HLX71, Placebo
- Drug · Other
- Lead sponsor
- Hengenix Biotech Inc
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Secaucus, New Jersey
- Conditions
- Healthy
- Interventions
- Vortioxetine, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 17 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Healthy Participants
- Interventions
- BMS-986421, Placebo
- Drug · Other
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Cypress, California
- Conditions
- Advanced Solid Tumors, Urothelial Carcinoma, Cholangiocarcinoma
- Interventions
- Drug ICP-192
- Drug
- Lead sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 9
- States / cities
- Tucson, Arizona • La Jolla, California • Aurora, Colorado + 6 more